menu
    • menu
    [{"orgOrder":0,"company":"Photocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Photocure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Photocure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Photocure \/ Undisclosed"},{"orgOrder":0,"company":"Photocure","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Photosensitiser","graph1":"Oncology","graph2":"Phase III","graph3":"Photocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Photocure \/ Photocure","highestDevelopmentStatusID":"10","companyTruncated":"Photocure \/ Photocure"},{"orgOrder":0,"company":"Photocure","sponsor":"Photocure","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NORWAY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Protoporphyrin IX","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Photocure","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Photocure \/ Photocure","highestDevelopmentStatusID":"9","companyTruncated":"Photocure \/ Photocure"},{"orgOrder":0,"company":"Photocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Protoporphyrin IX","graph1":"Undisclosed","graph2":"Phase I","graph3":"Photocure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Photocure \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Photocure \/ Undisclosed"},{"orgOrder":0,"company":"Photocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Protoporphyrin IX","graph1":"Oncology","graph2":"Phase II","graph3":"Photocure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Photocure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Photocure \/ Undisclosed"},{"orgOrder":0,"company":"Photocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NORWAY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Protoporphyrin IX","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Photocure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Photocure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Photocure \/ Undisclosed"},{"orgOrder":0,"company":"Photocure","sponsor":"Photocure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Protoporphyrin IX","graph1":"Oncology","graph2":"Phase III","graph3":"Photocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Photocure \/ Photocure","highestDevelopmentStatusID":"10","companyTruncated":"Photocure \/ Photocure"},{"orgOrder":0,"company":"Photocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Protoporphyrin IX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Photocure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Photocure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Photocure \/ Undisclosed"},{"orgOrder":0,"company":"Photocure","sponsor":"KARL STORZ Endoscopy-America","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Protoporphyrin IX","graph1":"Oncology","graph2":"Phase III","graph3":"Photocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Photocure \/ KARL STORZ Endoscopy-America","highestDevelopmentStatusID":"10","companyTruncated":"Photocure \/ KARL STORZ Endoscopy-America"},{"orgOrder":0,"company":"Photocure","sponsor":"Asieris Pharmaceuticals | Richard Wolf | Tigermed-Jyton","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Protoporphyrin IX","graph1":"Oncology","graph2":"Phase III","graph3":"Photocure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Photocure \/ Asieris Pharmaceuticals | Richard Wolf | Tigermed-Jyton","highestDevelopmentStatusID":"10","companyTruncated":"Photocure \/ Asieris Pharmaceuticals | Richard Wolf | Tigermed-Jyton"},{"orgOrder":0,"company":"Photocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NORWAY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Visonac","moa":"TLR-2\/TLR-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Photocure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Photocure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Photocure \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Photocure

    Menu

    Photocure

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Johns Hopkins University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

                            Details : Hexaminolevulinate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Bladder Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 29, 2024

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Johns Hopkins University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Asieris Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has A...

                            Details : Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.

                            Product Name : Cevira

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 20, 2023

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Asieris Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Asieris Pharmaceuticals | Richard Wolf | Tigermed-Jyton

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cance...

                            Details : Hexaminolevulinate HCl is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Bladder Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 31, 2022

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Asieris Pharmaceuticals | Richard Wolf | Tigermed-Jyton

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : KARL STORZ Endoscopy-America

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance ...

                            Details : Hexaminolevulinate HCl is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Bladder Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 25, 2015

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : KARL STORZ Endoscopy-America

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Detection of Bladder Tumors After 30 Min Instillation of Hexvix

                            Details : Hexaminolevulinate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Bladder Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2012

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Visonac

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With ...

                            Details : Visonac is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acne Vulgaris.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 04, 2011

                            Lead Product(s) : Visonac

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open Dose-finding Study of Oral Applied Hexaminolevulinate (HAL) Imaging in Patients With Suspicion or High...

                            Details : Hexaminolevulinate HCl is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Colonic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 29, 2011

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Recipient : Oslo University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment of Female Genital Erosive Lichen Planus(GELP) With Hexaminolevulinate PDT

                            Details : Hexaminolevulinate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Genital Lichen Planus.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 25, 2011

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Oslo University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia

                            Details : Hexaminolevulinate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uterine Cervical Dysplasia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 08, 2010

                            Lead Product(s) : Aminolevulinic Acid Hexylester

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Photocure

                            Norway arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Chloride

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients

                            Details : Sodium Chloride is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acne Vulgaris.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            July 12, 2010

                            Lead Product(s) : Sodium Chloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth